Latest Breaking News On - மிரியம் வெபர் மில்லர் - Page 5 : comparemela.com
Cleveland BioLabs, Inc Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Cleveland BioLabs, Inc Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
JUPITER, Fla., Feb. 4, 2021 /PRNewswire/ Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has named veteran business executive Julie Kampf as an Independent Member of its Board of Directors. Ms. Kampf will provide invaluable guidance as an Independent Member of Marizyme s Board of Directors as the company accelerates clinical and commercial development and puts a concurrent emphasis on revenue generation in the year ahead, said Dr. Neil J. Campbell, Marizyme s CEO, President and Board Member. She has a stellar reputation as a global business executive and thought leader in the life science arena.
Share this article
Share this article
JUPITER, Fla., Feb. 1, 2021 /PRNewswire/ Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has added two life science industry veterans to its senior management team. Roger Schaller has been appointed Executive Vice President (EVP) of Commercial Operations, and Amy Chandler has been promoted to Executive Vice President (EVP) for Regulatory Affairs and Quality Management Systems. Mr. Schaller s extensive experience overseeing commercial operations, business development and successful product development will be a tremendous asset to Marizyme as we focus on advancing commercial operations and revenue generation in the year ahead, said Dr. Neil J. Campbell, Marizyme s CEO, President and Board Member. His expertise will be invaluable in building Marizym